Cancer Moonshot Summit - June 29, 2016

View photos from the Fox Chase Cancer Center - Cancer Moonshot Summit.

Fox Chase Cancer Center is honored to have been selected by the U.S. Department of Health and Human Services to host the official Cancer Moonshot Summit for Region 3 (including Maryland, Delaware, Pennsylvania, Virginia, West Virginia and Washington DC) on Wednesday, June 29, 2016 .

This program, developed in cooperation with the  American Cancer Society and the U.S. Department of Health and Human Services, will feature a live-streamed address from Vice President Joe Biden, as well as appearances by cancer research luminaries in academia and industry.

Join Fox Chase's conversation on Twitter: #MOONSHOTFCCC
Discussion Questions and Instructions for #moonshotfccc [PDF]

Follow the Cancer Moonshot program at #CanServe.
For more on the White House Cancer Moonshot initiative and a live feed of the summit in Washington, DC,
visit https://www.whitehouse.gov/cancermoonshot

Agenda:

7:30 am
Registration and Continental Breakfast

8:30 am 

Joanne Grossi, Regional Director of the U.S. Department of Health and Human Services for Region III  

8:40 am

Wafik El-Deiry, MD, PhD, Deputy Cancer Center Director, Translational Research Program; Co-Leader, Molecular Therapeutics Program; William Wikoff Smith Endowed Chair in Cancer Research, Fox Chase Cancer Center

8:55 am

Richard I. Fisher, MD, President & CEO, Cancer Center Director, Senior Associate Dean, Lewis Katz School of Medicine, Temple University, Robert C. Young, MD, Chair in Cancer Research, Fox Chase Cancer Center

9:00 am

 
Vice President Joe Biden remarks (live-streamed from Howard University, Washington, D.C.) 

9:30 am

Bert Vogelstein, MD, Director of the Ludwig Center, Clayton Professor of Oncology and Pathology and a Howard Hughes Medical Institute investigator at The Johns Hopkins Medical Institutions, Johns Hopkins Medicine

9:50 am
Coffee Break

10:00 - 10:45 am
Research: The Foundation of Progress - In this panel, experts will highlight the importance of basic science discovery in cancer, and discuss impediments like flat funding, working group silos, and challenges of translating the bench to the bedside.

• Panel Chairs: William H. Chambers, PhD, Senior Vice President, Extramural Research and Training, The American Cancer Society, and Jonathan Chernoff, MD, PhD, Senior Vice President, Chief Scientific Officer, Fox Chase Cancer Center
• Discussion focus on "Research: The Foundation of Progress" - Panel members will discuss a host of questions including: How have approaches and advances in basic research impacted on patients with cancer? What are the challenges being faced in basic and translational research? Where should basic research be as a national priority and why? How to balance basic science with translation; how to support research better. Other discussion will include: How important is collaboration? What is the level of concern over data reproducibility? Where is morale and how are young careers in cancer research impacted? Discussion includes patient perspective with comments from cancer survivor Margaret Zuccotti. The major goal of this panel is to discuss the importance of scientific discovery for the needed progress in prevention, early detection, diagnosis and therapy. We need a sustainable pipeline of discovery and workforce as a fundamental part of the fight against cancer.
• Panel Members:
  • Jane Azizkhan-Clifford, PhD, Professor and Chair, Associate Dean for Medical Student Research, Drexel University College of Medicine
  • Wafik S. El-Deiry, MD, PhD, FACP, Deputy Cancer Center Director, Fox Chase Cancer Center
  • Xavier Grana-Amat, PhD, Associate Professor, Fels Institute for Cancer Research and Molecular Biology, Lewis Katz School of Medicine at Temple University
  • Yvonne Paterson, PhD, Perelman School of Medicine at the University of Pennsylvania, Associate Dean for Research and Professor, School of Nursing, University of Pennsylvania
  • George C. Prendergast, PhD, President/CEO, The Lankenau Institute for Medical Research, Editor-in-Chief, Cancer Research
  • Glenn F. Rall, PhD, Associate Chief Academic Officer, Director, Postdoctoral Program, Fox Chase Cancer Center
  • Frank J. Rauscher, III, PhD, Deputy Director, The Wistar Institute Cancer Center
  • Gavin P. Robertson, PhD, Director, Melanoma and Skin Cancer Center, Penn State College of Medicine
  • Joseph R. Testa, PhD, FACMG, Co-Leader, Cancer Biology, Fox Chase Cancer Center
  • David Wiest, PhD, Deputy Chief Scientific Officer, Co-Leader, Blood Cell Development and Function, Fox Chase Cancer Center
  • M. Raza Zaidi, PhD, Assistant Professor, Fels Institute for Cancer Research and Molecular Biology, Lewis Katz School of Medicine at Temple University
  • Margaret Zuccotti, Stage IV Inflammatory Breast Cancer Survivor

10:45 - 11:30 am
Data Sharing in Precision Oncology - Vice President Biden has urged everyone to collaborate as we begin a new era in the fight against cancer. This panel will explore both the potential and challenges due to the recent technological advances in multiple testing platforms, liquid biopsies, clinical guidelines, electronic records, and data retrieval and integration.

• Panel Chairs: Wafik S. El-Deiry, MD, PhD, FACP, Deputy Cancer Center Director, Fox Chase Cancer Center and Richard Snyder, MD, Senior Vice President and Chief Medical Officer, Independence Blue Cross
• Discussion focus on "Data Sharing in Precision Oncology" - Panel members will discuss a host of questions including: How have technological advances provided opportunities to improve patient care? What are the challenges being faced in clinical implementation of precision medicine and in research? How is the value of molecular testing being demonstrated and what is needed? Other discussion will include: Why is data sharing crucial? How important is collaboration? There will be some discussion of progress by national precision medicine networks and consortiums and discussion of the need for national solutions; common platforms for data sharing; data access. There will be some discussion on the need for National Guidelines in genomic medicine. More broadly what are the implications of genomic testing for populations at risk for disease. The major goal of this panel is to discuss the excitement around technological advances in precision medicine, and to bring out obstacles and challenges to making progress. Additional points to be discussed: different testing platforms, costs of tests, limited tissue, complex genomics and results (role of tumor boards; genetic counseling), variable patient responses, difficulties with access to data from EMRs across platforms, tumor heterogeneity, parallel efforts, regulatory hurdles.
• Panel:
  • Igor Astsaturov, MD, PhD, Assistant Professor, Fox Chase Cancer Center
  • Tabari Baker, PhD, Research Scientist, Molecular Science Liaison, CARIS Life Sciences
  • Kennedy Cliffe, Associate Vice President, CARIS Life Sciences
  • Mary B. Daly, MD, PhD, FACP, Chair, Clinical Genetics, Director of the Risk Assessment Program, Fox Chase Cancer Center
  • Luis Alberto Diaz, Jr, MD, co-Founder of Personal Genome Diagnostics and Associate Professor of Oncology, Johns Hopkins Medicine
  • Keri J. Donaldson, MD, Assistant Professor, Division of Clinical Pathology, Penn State Health, Milton S. Hersey Medical Center
  • Arlene A. Forastiere, MD, Senior Vice President, Medical Affairs, Eviti; Sydney Kimmel Comprehensive Cancer Center
  • Glenn S. Gerhard, MD, Chair, Department of Medical Genetics and Molecular Biochemistry, Lewis Katz School of Medicine at Temple University
  • Michael Italia, MS, Director Customer Solutions, Syapse
  • Eric A. Ross, PhD, ScM, Assistant Vice President of Biometrics and Information Sciences, Fox Chase Cancer Center
  • Phil Stephens, PhD, Chief Scientific Officer, Foundation Medicine
  • AmirAli Talasaz, PhD, Co-Founder, President, Guardant Health

11:30 - 12:15 pm
Clinical Trials and Patient Advocacy - All these advances will be for naught if we can’t get patients enrolled in clinical trials, and the challenges to enrollment are myriad. Too few trials are opened, access to care issues arise, and the perception of trials remains negative. How can patient advocacy groups help? How can institutions and health care teams address these issues?

• Panel Chairs: Richard I. Fisher, MD, President and CEO, Fox Chase Cancer Center and Robert Carlson, MD, CEO, National Comprehensive Cancer Network, Attending Physician, Fox Chase Cancer Center
• Discussion focus on "Clinical Trials and Patient Advocacy" - Panel members will discuss a host of questions including: How have advances in clinical research impacted on patients with cancer? What are the challenges being faced in clinical research and possible solutions? What obstacles do patients face in 2016 in general and with respect to clinical trials? There will be discussion of issues with access to care, cost of drugs, too few trials, limited enrollment in open clinical trials, too few drugs in era of genomics, communication with and support of patients and their families. There will be some discussion of current trends including large and complex early phase trials, central IRBs, regulatory hurdles. What can be improved? Is the drug/device oversight and approval process working well. Discussion includes patient perspective with comments from the cancer survivors Pam Kania and Melissa Kartasevich. The major goal of this panel is to discuss the major issues with clinical trials along with possible solutions. A second goal is to discuss challenges patients face in general and how the modern day health care team and patient advocacy addresses them.
• Panel:
  • Abbas El-Sayed Abbas, MD, Vice Chair and Associate Professor, Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University
  • Adam Batchelor, Vice President, Marketing & Business Development, The American College of Financial Services, American Cancer Society Cancer Action Network National Ambassador Team
  • Hossein Borghaei, DO, Chief, Thoracic Oncology, Fox Chase Cancer Center
  • Michael Bromberg, MD, PhD, Chief, Section of Hematology and Oncology, Lewis Katz School of Medicine at Temple University
  • Lori J. Goldstein, MD, FASCO, Director, The Naomi and Phil Lippincott Breast Evaluation Center, Fox Chase Cancer Center
  • Raymond J. Hohl, MD, PhD, Director, Penn State Hershey Cancer Institute
  • Pam Kania, Two-Time Cancer Survivor (soft tissue leiomyosarcoma and breast cancer),  Regional Administrator, U.S. Department of Health and Human Services, Health Resources and Services Administration
  • Melissa Kartasevich, Stage IV Pancreatic Cancer Survivor, Clinical Trial Participant
  • Margaret von Mehren, MD, Physician Director, Clinical Trials Office, Chief of Sarcoma Program, Fox Chase Cancer Center
  • Joshua E. Meyer, MD, Radiation Oncologist, Fox Chase Cancer Center
  • Edith Mitchell, MD, FACP, Director, Center to Eliminate Cancer Disparities, Program Leader, Gastrointestinal Oncology, NCI Cancer Moonshot Blue Ribbon Panel, Jefferson Health, President, National Medical Association.
  • Elizabeth Plimack, MD, MS, Director of Genitourinary Clinical Research, Fox Chase Cancer Center
  • John "Drew" Ridge, MD, PhD, FACS, Chief, Head & Neck Surgery, President of the Medical Staff, Fox Chase Cancer Center

12:15 pm
Program Concludes.